• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    process for the production of 1-triazole-2-butanol derivatives. the present invention relates to a process for the production of the compound of formula 1 in higher yield by the reaction of adding epoxytriazole ring opening with amine under mild conditions without the use of a large excess of 4-methylenepiperidine. the process for the production of (2r, 3r) -2- (2,4-difluorophenyl) -3- (4-methylenepiperidin-1-yl) -1- (1h-1,2,4-triazol-1-yl ) butan-2-ol or an acid addition salt thereof comprises the reaction of (2r, 3s) -2- (2,4-difluorophenyl) -3-methyl-2 - [(1h-1,2,4- triazol-1-yl) methyl] oxirane with an acid addition salt of 4-methylenepiperidine in a reaction solvent in the presence of an alkali metal hydroxide or an alkaline earth metal selected from the group consisting of lithium, sodium, calcium and strontium, or a hydrate of these.
    公开号:BR112013004827B1
    申请号:R112013004827-1
    申请日:2011-08-31
    公开日:2020-03-31
    发明作者:Mitsuo Mimura；Masahito Watanabe；Nobuo Ishiyama；Takuya Yamada
    申请人:Kaken Pharmaceutical Co., Ltd.；
    IPC主号:
    专利说明:

    Descriptive Report of the Invention Patent for PROCESSES FOR THE PRODUCTION OF 1-TRIAZOL-2-BUTANOL DERIVATIVES.
    Technical Field [001] The present invention relates to processes for the production of (2R, 3R) -2- (2,4-difluorophenyl) -3- (4-methylenepiperidin-1-yl) -1- (1H1, 2,4-triazol-1-yl) butan-2-ol (non-proprietary name (INN): Efinaconazole, hereinafter sometimes abbreviated as KP-103) which is the compound represented by general formula 1 and known to be effective against mycotic diseases in humans and animals (the compound described in Example 1 in Patent Document 1) or salts of this compound.
    [002] [Formula 1]
    Formula 1
    Prior Art [003] Methods for obtaining amino alcohols by epoxy ring opening addition reaction with amines are generally carried out at elevated temperature for an extended time using a large excess of amines. Since a large excess of amines is used, conventional methods give rise to a large amount of by-products and require the amine recovery step; as a result, if amines are expensive, conventional methods are desirable not only from the point of view of production cost, but also as an industrial production process. In order to carry out an intensified reactivity, it was proposed
    Petition 870190070655, of 7/24/2019, p. 13/34
    2/16 that the reaction described above is performed using Lewis acids, but the Lewis acids that can be used are expensive or unstable and are not suitable for industrial use; perchlorates or the like are highly toxic and dangerous and because of this low level of safety, they have presented several problems such as the need to take greater care in use (Non-Patent Documents 1 and 2). It has also been reported that through the use of lithium bromide, reactivity at room temperature under a solvent-free condition can be improved (Non-Patent Document 3). The method reported in this document uses amines and epoxides that are liquid at normal temperature, so its success is probably due to the reaction of the starting materials in high concentrations under a solvent-free condition. It follows that this method is not applicable to amines and epoxides that are solid at normal temperature, especially those with high melting points.
    [004] Turning now to the compound of formula 1, it is produced by the ring-opening reaction of an epoxide with an amine as described in Patent Document 1. In this production method, (2R, 3S) -2 - (2,4-difluorophenyl) -3-methyl-2 - [(1H-1,2,4triazol-1-yl) methyl] oxirane (below sometimes abbreviated as epoxytyriazole) is used as epoxide and 4-methylenepiperidine ( below sometimes abbreviated as 4-MP) is used as the amine. In this method, the ring opening addition reaction uses a large excess of
    4-MP in water and involves prolonged heating under reflux, thus it has the disadvantage that a large amount of by-products is generated during the reaction and needs to be removed. As another problem, 4-methylenepiperidine, which is produced by the method described in Patent Document 2, is obtained when dissolved in water, so its purity is low enough to affect reactivity
    Petition 870190070655, of 7/24/2019, p. 14/34
    3/16 and impurities are inevitably generated by the heat applied in the isolation step through distillation.
    List of Citations
    Patent Documents [005] Patent Document 1: WO94 / 26734 pamphlet [006] Patent Document 2: WO97 / 11939 pamphlet
    Non-Patent Documents [007] Non-Patent Document 1: Synthesis, 2004, No. 10, pp
    1563-1565 [008] Non-Patent Document 2: J. Org. Chem., 2007, vol. 72, pp
    3713-3722 [009] Non-Patent Document 2: Eur. J. Org. Chem. Chem.,
    2004, No. 17, pp 3597-3600
    Summary of the Invention Technical Problem [0010] An objective of the present invention is to provide a process for the production of the compound of formula 1 in higher yield and with reduced generation of by-products through the ring opening addition reaction of (2R, 3S) - 2- (2,4-difluorophenyl) -3-methyl-2 - [(1H-1,2,4triazol-1-yl) methyl] oxirane with 4-methylenepiperidine under mild conditions without using a large excess of 4- methylene piperidine.
    Solution to the Problem [0011] As a result of intensive studies, the present inventors have observed the following: if 4-methylenepiperidine is converted to an acid addition salt of 4-methylenepiperidine, it is free of any possible impurities that may have been included in the acquisition stage of 4-methylenepiperidine and can be isolated as a highly pure solid, with the consequent result that the purity of 4-methylenepiperidine which is used as a starting material in the epoxitriazole ring opening addition reaction with
    Petition 870190070655, of 7/24/2019, p. 15/34
    4/16 amine can be improved; and if this epoxythriazole ring opening addition reaction with amine is carried out in a reaction solvent in the presence of an alkali metal hydroxide or a specific alkaline earth metal, there is no need to use a large excess of 4-methylenepiperidine and the compound of formula 1 can be produced under mild conditions to provide greater yield while reducing the generation of by-products. The present invention was carried out on the basis of these findings.
    Description of Modalities [0012] The process of the present invention is described below in detail.
    [0013] The present invention relates to a process for producing the compound of formula (1) which, as formulated below, comprises the reaction of (2R, 3S) -2- (2,4-difluorophenyl) -3-methyl -2 - [(1H-1,2,4-triazol-1yl) methyl] oxirane with a 4-methylenepiperidine acid addition salt in a reaction solvent, in the presence of an alkali metal hydroxide or an alkali metal selected from the group consisting of lithium, sodium, calcium, strontium and or a hydrate of the hydroxide of: [0014] [Formula 2]

    Formula (1) [0015] (where HX means the acid in the acid addition salt)
    Starting Materials in the Process of the Present Invention [0016] The process of the present invention can be carried out using the starting compounds in any amounts ranging from the gram level to the ton level, and the amount of the solvent can be determined according to the amounts of the compounds
    Petition 870190070655, of 7/24/2019, p. 16/34
    5/16 starter to be used.
    [0017] (2R, 3S) -2- (2,4-difluorophenyl) -3-methyl-2 - [(1 H-1,2,4-triazol-1yl) methyl] -oxyrane can be obtained by the method described in JP 2-191262 A.
    [0018] The acid addition salt of 4-methylenepiperidine is represented by the following formula:
    [0019] [formula 3]
    NH -HX [0020] In the above formula, HX means the acid in the acid addition salt and the acid that forms the acid addition salt of 4-methylenepiperidine can be basically any acid that forms salts with amines and examples include, but are not limited to these are inorganic salts such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, boric acid, chloric acid and carbonic acid, as well as organic acids such as formic acid, acetic acid, trifluoroacetic acid , propionic acid, oxalic acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid. Preferred examples of the acid include hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, and trifluoroacetic acid, and hydrobromic acid or hydroiodic acid is more preferable.
    [0021] To obtain the 4-methylenepiperidine acid addition salt,
    4-methylenepiperidine and an acid corresponding to the acid addition salt can be reacted in the usual way.
    [0022] From the point of view of production on an industrial scale, 4 methylene piperidine can preferably be produced by the method described in the WO 97/11939 pamphlet. The 4-methylene piperidine produced by this method is obtained when dissolved in water and contains the impurities that were generated by the heat applied during the isolation through distillation. In contrast, according to the method of
    Petition 870190070655, of 7/24/2019, p. 17/34
    6/16 duction described below, the 4methylene piperidine acid addition salt is free of the above-mentioned impurities and can be isolated as a highly pure solid.
    [0023] Thus, a preferred process for the production of the 4-methylenepiperidine acid addition salt comprises the following two steps:
    [0024] reaction of a solution of 4-methylenepiperidine with an acid corresponding to the acid addition salt; and [0025] after optional extraction by distillation of the solvent, purification of the resulting product by crystallization or washing in suspension.
    [0026] Examples of the 4-methylenepiperidine solution used in step (1) include an aqueous solution, an alcohol solution (for example, methanol solution), and a mixed solvent solution consisting of water and alcohol or the like. The amount to be used of an acid that corresponds to the acid addition salt is preferably 0.9 to 1.0 equivalent based on 4-methylenepiperidine. The reaction conditions for step (1) are such that it is carried out at a temperature ranging from 0 ° C to around the ambient temperature for a period ranging from 15 minutes to several hours.
    [0027] After step (1), the solvent can optionally be removed in the usual manner, typically under reduced pressure and at room temperature or with heating. If the water content of the reaction system is reduced, a suitable method can be adopted, such as the use of a desiccant or azeotropy of a mixture with toluene.
    [0028] Purification by crystallization or washing in suspension in step (2) may involve recrystallization after dissolving with a solvent or washing the crystal with a solvent in suspension after being obtained by extraction by distillation of the solvent or by filtration.
    Petition 870190070655, of 7/24/2019, p. 18/34
    7/16 [0029] The specific conditions for the production method vary with the type of the acid addition salt. In the case of hydrobromide and hydrochloride, the solvent is distilled off after the reaction in step (1) and, after that, the resulting crystal is washed with suspended acetone and extracted by filtration. In the case of p-toluenesulfonate, the solvent is distilled off after the reaction in step (1), after which the residue is dissolved in a liquid mixture of ethyl acetate / isopropanol (10: 1) and then subjected to recrystallization . In the case of iodhydride, trifluoroacetate and nitrate, the solvent is distilled off to dryness after the reaction in step (1) and then diisopropyl ether is added to the residue and the washing is carried out in suspension.
    Reaction Conditions for the Process of the Invention [0030] The 4-methylenepiperidine acid addition salt is typically used in amounts ranging from 1 to 5 equivalents, preferably from 1 to 1.5 equivalents, based on epoxythriazole.
    [0031] Examples of the alkali metal hydroxide or an alkaline earth metal to be used in the reaction preferably include lithium hydroxide, sodium hydroxide, calcium hydroxide, and strontium hydroxide, as well as their hydrates. More preferable are lithium hydroxide, calcium hydroxide, and their hydrates, and even more preferable are lithium hydroxide and its hydrates.
    [0032] The amount to be used of the above-mentioned hydroxide of an alkali metal or an alkaline earth metal varies with the type and basicity of the specific compound to be used and typically ranges from 1 to 5 equivalents, preferably from 1 to 1.5 equivalent, based on the 4-methylenepiperidine acid addition salt.
    [0033] Examples of the reaction solvent include: alcohols such as methanol, ethanol, isopropanol and 1-butanol; polar aprotic solvents (as examples, esters such as ethyl acetate and butyl acetate;
    Petition 870190070655, of 7/24/2019, p. 19/34
    8/16 amides such as N, N-dimethylformamide, N, N-dimethylacetamide, and Nmethylpyrrolidone; ethers such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, and cyclopentyl methyl ether, other solvents such as acetonitrile, dimethyl sulfoxide, nitromethane, and 4-methyl-2-pentanone); mixtures of two or more of these solvents; and the mixed solvents consisting of water and at least one of the aforementioned solvents. Preferred reaction solvents are acetonitrile, 1,2dimethoxyethane, cyclopentyl methyl ether, isopropanol, 1-butanol, and 4methyl-2-pentanone; most preferred are acetonitrile, 1,2-dimethoxyethane, cyclopentyl methyl ether, and isopropanol; even more preferred are acetonitrile and cyclopentyl methyl ether.
    [0034] The reaction is carried out at temperatures in the range of 0 ° C to
    150 ° C with cooling, at room temperature, or with optional heating. The reaction time varies with the reaction temperature, the solvent used, and other factors, but typically ranges from 1 to 24 hours. The reaction can be performed at any pressure, but it is typically performed at normal pressure.
    [0035] The compound obtained by the reaction can be purified in the usual way as by recrystallization or chromatography.
    [0036] If desired, the compound obtained from formula 1 can be converted to a salt with an inorganic acid such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid or hydrobromic acid, or an organic acid such as fumaric acid, maleic acid , acetic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid or p-toluenesulfonic acid.
    [0037] In the following pages, the present invention is described more specifically by way of Examples, but it should be understood that the present invention is in no way limited by these examples.
    Petition 870190070655, of 7/24/2019, p. 20/34
    9/16
    Production Examples 1 Production of 4-metjlenopjperjdjna hydrobromide (4-MP-HBr) [0038] 4-Methylenepiperidine (4-MP) in a methanol / water mixture at a concentration of 0.8 M was prepared by the method described in the pamphlet WO 97/11939 and 500 ml (0.4 mol) of the solution were cooled with stirring in an ice bath. After that,
    61.3 g (0.36 mol) of 48% hydrobromic acid was added in several portions to the cooled solution, which was stirred in an ice bath for one hour. Then, the solvents were distilled off by heating under reduced pressure, after which a white crystal precipitated. Subsequently, 50 ml of toluene was added and the solvent was distilled off by heating under reduced pressure to effect azeotropic dehydration; after performing this procedure twice, 192 ml of acetone was added and the mixture was stirred in an ice bath for two hours. Then, the crystal was extracted by filtration, washed with 60 ml of acetone (when cooled in an ice bath), dried with air at room temperature, and further dried under reduced pressure at 40 ° C for 12 hours to provide a crystal colorless 4-MP ^ HBr in an amount of 58 g (yield, 90%). [0039] 1H-NMR (500 MHz, CDCh) [0040] δ: 2.62 (4H, t, J = 6.09 Hz), 3.26 (4H, t, J = 6.09 Hz), 4 , 90 (2H, s), 9.18 (1H, br).
    [0041] melting point (DSC): 147 to 147.9 ° C
    Production 2
    Production of 4-methylenopjperidjna-p-toluenesulfonate (4MP-PTSA) [0042] 4-Methylenopiperidine (4-MP) as prepared by the method described in the WO 97/11939 pamphlet was subjected to an operation
    Petition 870190070655, of 7/24/2019, p. 21/34
    10/16 dehydration and the resulting 4-MP (9.7 g, 0.1 mol) was dissolved in isopropanol (IPA) (50 ml); to the resulting solution, p-toluenesulfonic acid monohydrate (PTSA ^ H2O) (18.1 g, 0.095 mol) in IPA (80 ml) was added and after stirring the mixture at room temperature for 30 minutes (weakly exothermic), IPA was distilled off under reduced pressure and the residue was dissolved in a mixture of ethyl acetate / IPA (10: 1) (250 ml) with heating. After cooling to room temperature, the solution was left to stand at 0 to 5 ° C for 20 hours and the precipitating crystal was filtered off, washed and dried to provide a 4MP ^ PTSA white crystal in an amount of 23, 34 g (yield, 91.2%).
    [0043] 1H-NMR (400 MHz, DMSO-d6) [0044] δ: 2.29 (3H, s), 2.35 (4H, t, J = 6.4 Hz), 3.08 (4H, t, J = 6.4
    Hz), 4.85 (2H, s), 7.13 (2H, d, J = 8.2 Hz), 7.49 (2H, d, J = 8.2 Hz), 8.58 (2H, br s).
    Production 3
    Production of 4-methylenepiperidine hydrochloride (4-MP-HCl) [0045] 4-Methylenepiperidine (4-MP) as prepared by the method described in the WO 97/11939 pamphlet was subjected to a dehydration operation and 400 g (4, 12 moles) of the resulting 4-MP were cooled with stirring in an ice bath. Subsequently, 350 ml (4.08 mmols) of concentrated hydrochloric acid were added to the cooled solution, which was further stirred in an ice bath. After concentration under reduced pressure, 300 ml of toluene was added and the mixture was concentrated under reduced pressure to effect azeotropic dehydration; after performing this procedure three times, 300 ml of acetone was added and the mixture was washed in suspension with ice cooling. The crystal was filtered off, washed with acetone, and dried under reduced pressure at room temperature to provide 4-methylenepiperidine hydrochloride (4-MP-HCl)
    Petition 870190070655, of 7/24/2019, p. 22/34
    11/16 in an amount of 336.8 g (yield, 46%).
    [0046] 1H-NMR (500 MHz, CDCh) [0047] δ: 2.58 (4H, t, J = 6.1 Hz), 3.22 (4H, t, J = 6.1 Hz), 4 , 89 (2H,
    s), 9.70 (1H, br s).
    Production 4
    Production of 4-methylenepiperidine (4-MP-HI) [0048] 4-Methylenepiperidine (4-MP) in a 0.66 M concentration of methanol / water was prepared by the method described in the WO 97 pamphlet / 11939 and 20 ml (13.19 mmols) of the solution were cooled with stirring in an ice bath. After that, 2.66 g (11.84 mmols) of 57% hydroiodic acid was added to the cooled solution, which was stirred in an ice bath for 15 minutes. After concentration under reduced pressure, 1.6 ml of toluene was added and the mixture was concentrated under reduced pressure to effect azeotropic dehydration; this procedure was performed twice, after which a white solid was precipitated. Diisopropyl ether (6 ml) was added and the crystal was washed in suspension at room temperature for one hour. Then, the crystal was extracted by filtration, washed with diisopropyl ether, and dried under reduced pressure at room temperature to provide 4-methylenepiperidine iodide (4-MP-HI) in an amount of 2.66 g (yield, 90%).
    [0049] 1 H-NMR (500 MHz, CDCl3) [0050] δ: 2.66 (4H, t, J = 6.1 Hz), 3.31 - 3.33 (4H, m), 4.91 (2H, s),
    8.34 (1H, br s).
    Production 5 Production of 4-methylenopjperidjna trifluoroacetate (4-MP-TFA) [0051] The reaction was carried out using the same method as described above, except that 57% hydroiodic acid was replaced by
    1.35 g (11.87 mmols) of trifluoroacetic acid (TFA), which provides tri
    Petition 870190070655, of 7/24/2019, p. 23/34
    12/16 4-methylenepiperidine fluoroacetate (4-MP-TFA) in an amount of 2.55 g (yield, 92%).
    [0052] 1H-NMR (500 MHz, CDCh) [0053] δ: 2.50 (4H, t, J = 6.1 Hz), 3.16 (4H, t, J = 6.1 Hz), 4 , 89 (2H,
    s), 9.52 (1H, br s).
    Production 6
    Production of 4-methylenepiperidine nitrate (4-MP-HNÜ3) [0054] The reaction was carried out using the same method as described above, except that 57% hydroiodic acid was replaced by 1.08 g (11.87 mmols) 69% nitric acid, which provides 4-methylpiperidine nitrate (4-ΜΡΉΝΟ3) in an amount of 1.87 g (yield, 89%).
    [0055] 1 H-NMR (500 MHz, CDCl3) [0056] δ: 2.53 (4H, t, J = 6.1 Hz), 3.28 (4H, t, J = 6.1 Hz), 4.89 (2H,
    s), 8.85 (1H, br s).
    Example 1
    Production of (2R, 3R) -2- (2,4-difluorophenyl) -3- (4-methylenepiperidin-1 yl) -1 - (1H - 1,2,4-triazol-1-yl) butan-2 -ol (KP-103) [0057] 21.26 g (119.4 mmols) of 4-methylenepiperidine hydrobromide (4-MP-HBr) obtained in Production 1 and 2.859 g (119.4 mmols) of lithium hydroxide they were added to 80 ml of acetonitrile and stirred for a while. Then, 20 g (79.6 mmoles) of (2R, 3S) -2 (2,4-difluorophenyl) -3-methyl-2 - [(1H-1,2,4-triazol-1-yl) methyl ] oxirane were added and the mixture was heated under reflux in an oil bath (external temperature: 100 ° C) for 14 hours. After the reaction was complete, ethanol and distilled water were added to the reaction mixture, after which a crystal was precipitated. Then, the crystal was extracted by filtration, washed with 40 ml of an ethanol / water mixture, dried with air at room temperature, and further dried under reduced pressure at 40 ° C for 12 hours to provide a crystal
    Petition 870190070655, of 7/24/2019, p. 24/34
    13/16 light yellow KP-103 in an amount of 24.2 g (yield, 87.3%, HPLC purity, 95.3%).
    [0058] 1H-NMR (500 MHz, CDCh) [0059] δ: 0.96 (3H, dd, J = 2.68, 7.08 Hz), 2.13 - 2.26 (4H, m), 2.35 (2H, br), 2.70 (2H, br), 2.90 - 2.94 (1H, q, J = 7.08 Hz), 4.64 (2H, s), 4.82 (1H, dd, J = 0.73, 14.39 Hz), 4.87 (1H, dd, J = 0.73, 14.39 Hz), 5.45 (1H, s), 6.72 - 6.81 (2H, m), 7.51 (1H, dt, J = 6.59, 9.03 Hz), 7.78 (1H, s), 8.02 (1H, s).
    [0060] FAB-MS m / z: 349 [M + H] + [0061] melting point: 86 to 89 ° C [0062] optical rotation [Q] d 25 -87 to -91 ° (C = 1, 0, methanol)
    Example 2 [0063] 0.50 g (1.99 mmol) of epoxythriazole, 0.53 g (2.98 mmol) of 4-methylenepiperidine hydrobromide (4-MP-HBr) and 0.07 g (2.96 mmols) of lithium hydroxide were added to 2 ml of acetonitrile and heated under reflux in an oil bath (external temperature, 100 ° C) for 14 hours. After distillation, the solvent of the reaction mixture under reduced pressure, water and ethyl acetate were added to the residue and an organic layer was separated. The organic layer was concentrated under reduced pressure and purified by column chromatography on silica gel with a hexane / ethyl acetate solvent (1: 1) to provide KP-103 in an amount of 0.59 g (yield, 86% ).
    Example 3 [0064] The reaction was carried out using the same method as in
    Example 2, except that lithium hydroxide was replaced with 0.22 g (2.97 mmols) of calcium hydroxide, providing KP-103 in an amount of 0.57 g (yield, 82%).
    Example 4 [0065] The reaction was carried out for 19 hours by the same method
    Petition 870190070655, of 7/24/2019, p. 25/34
    14/16 all as in Example 2, except that lithium hydroxide was replaced by 0.36 g (2.98 mmols) of strontium hydroxide, providing KP-103 in an amount of 0.47 g (yield, 68% ).
    Example 5 [0066] 0.50 g (1.99 mmol) epoxythriazole, 0.53 g (2.98 mmol) 4-methylenepiperidine hydrobromide (4-MP-HBr) and 0.13 g (2.96 mmols) of lithium hydroxide monohydrate were added to 2 ml of acetonitrile and heated under reflux in an oil bath (external temperature, 100 ° C) for 14 hours. A sample of the reaction mixture was subjected to measurement by HPLC to determine the conversion (percentage of relative area of KP-103); KP-103 was verified to have been generated in 81% conversion.
    Example 6 [0067] The reaction was carried out using the same method as in
    Example 2, except that acetonitrile was replaced by 2 ml of cyclopentyl methyl ether (CPME), providing KP-103 in an amount of 0.63 g (yield, 91%).
    Example 7 [0068] The reaction was carried out using the same method as in
    Example 2, except that acetonitrile was replaced with 2 ml of 1,2dimethoxyethane (DME), providing KP-103 in an amount of 0.55 g (yield, 79%).
    Example 8 [0069] The reaction was carried out using the same method as in
    Example 2, except that acetonitrile was replaced by 2 ml of 1-butanol, providing KP-103 in an amount of 0.59 g (yield, 72%).
    Example 9 [0070] The reaction was carried out using the same method as in
    Example 2, except that acetonitrile was replaced by 2 ml of isopro
    Petition 870190070655, of 7/24/2019, p. 26/34
    15/16 panol, providing KP-103 in an amount of 0.50 g (yield, 86%).
    Example 10 [0071] The reaction was carried out using the same method as in
    Example 2, except that acetonitrile was replaced with 2 ml of 4-methyl2-pentanone (MIBK), providing KP-103 in an amount of 0.61 g (yield, 88%).
    Example 11 [0072] The reaction was carried out using the same method as in
    Example 2, except that 4-methylenepiperidine hydrobromide (4-MP-HBr) was replaced by 0.40 g (2.99 mmols) of the 4-methylenepiperidine hydrochloride (4-MP-HCl) obtained in Production 3, where KP- 103 was obtained in an amount of 0.47 g (yield, 67%).
    Example 12 [0073] The reaction was carried out using the same method as in
    Example 2, except that 4-methylenepiperidine hydrobromide (4-MP-HBr) was replaced by 0.67 g (2.99 mmols) of the 4-methylenepiperidine iodhydride (4-MP-HI) obtained in Production 4, after which KP103 was obtained in an amount of 0.62 g (yield, 90%).
    Example 13 [0074] The reaction was carried out using the same method as in
    Example 2, except that 4-methylenepiperidine hydrobromide (4-MP-HBr) was replaced by 0.63 g (2.98 mmol) of the 4-methylenepiperidine trifluoroacetate (4-MP-TFA) obtained in Production 5, after which KP103 it was obtained in an amount of 0.54 g (yield, 90%).
    Example 14 [0075] The reaction was carried out using the same method as in
    Example 2, except that 4-methylenepiperidine hydrobromide (4-MP-HBr) was replaced by 0.48 g (3.00 mmols) of the 4-methylenepiperidine nitrate (4-MP-HNQs) obtained in Production 6, after which KP
    Petition 870190070655, of 7/24/2019, p. 27/34
    16/16
    103 was obtained in an amount of 0.49 g (yield, 71%). Example 15 [0076] The reaction was carried out for 18 hours using the same method as in Example 2, except that titanium hydroxide was replaced by 0.12 g (2.98 mmols) of sodium hydroxide and 4-methylenepiperidine hydrobromide ( 4-MP-HBr) was replaced by 0.67 g (2.99 mmols) of the 4-methylenepiperidine iodide (4-MP-HI) obtained in Production 4, after which KP-103 was obtained in an amount of 0 , 51 g (yield, 73%).
    Industrial Applicability [0077] The problems presented by the conventional process for the production of the compound of formula 1 were the inclusion of impurities in the acquisition stage of the starting material 4methylene piperidine and the generation of by-products during the production of the compound of formula 1. In contrast, according to the method of the present invention, an acid addition salt of 4-methylenepiperidine is used as a starting material for the production of the compound of formula 1, thereby being free of any impurities that may have been included in the stage of obtaining 4-methylene-piperidine and this allows the use of a highly pure solid. In addition, the addition of amine ring opening to epoxitriazole is promoted in the method of the present invention, so there is no need to use a large excess of 4-methylenepiperidine and the compound of formula 1 can be produced under mild conditions with greater yield while reducing the generation of by-products. Consequently, the method of the present invention allows the compound of formula 1 to be produced on an industrial scale.
    权利要求:
    Claims (7)
    [1]
    1. Process for the production of (2R, 3R) -2- (2,4difluorophenyl) -3- (4-methylenepiperidin-1-yl) -1- (1H-1,2,4-triazol-1-yl) butan-2ol or an acid addition salt thereof, characterized by the fact that it comprises the reacting (2R, 3S) -2- (2,4-difluoro-phenyl) -3-methyl-2 - [(1H-1, 2,4triazol-1-yl) methyl] oxirane with an acid addition salt of 4methylenepiperidine in a reaction solvent in the presence of an alkali metal hydroxide or an alkaline earth metal selected from the group consisting of lithium, calcium and strontium, or such a hydrate.
    [2]
    Process according to claim 1, characterized in that the hydroxide of an alkali metal or an alkaline earth metal is lithium hydroxide.
    [3]
    Process according to claim 1 or 2, characterized in that the acid addition salt of 4-methylenepiperidine is 4-methylene-piperidine hydrobromide or 4-methylene-piperidine ihydride.
    [4]
    Process according to claim 3, characterized in that the acid addition salt of 4-methylenepiperidine is 4-methylenepiperidine hydrobromide.
    [5]
    Process according to any one of claims 1 to 4, characterized in that the reaction solvent is acetonitrile,
    1,2-dimethoxyethane, cyclopentyl methyl ether, isopropanol,
    Petition 870190070655, of 7/24/2019, p. 29/34
    2/2
    1-butanol, or
    4-methyl-2-pentanone.
    [6]
    Process according to claim 5, characterized in that the reaction solvent is acetonitrile or cyclopentyl methyl ether.
    [7]
    7. Process for the production of (2R, 3R) -2- (2,4difluorophenyl) -3- (4-methylenepiperidin-1-yl) -1- (1H-1,2,4-triazol-1-yl) butan-2ol or an acid addition salt thereof, characterized by the fact that it comprises reacting (2R, 3S) -2- (2,4-difluoro-phenyl) -3-methyl-2 - [(1H-1,2 , 4triazol-1-yl) methyl] oxirane with 4-methylenepiperidine hydroiodide in a reaction solvent in the presence of sodium hydroxide.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112013004827B1|2020-03-31|PROCESS FOR THE PRODUCTION OF 1-TRIAZOL-2-BUTANOL DERIVATIVES
    TWI454471B|2014-10-01|Processes to make apoptosis promoters
    US10479776B2|2019-11-19|Process for the preparation of Efinaconazole
    US20040049053A1|2004-03-11|Process for the prepartion of 1,2-benzisoxazole-3-acetic acid
    ES2396203T3|2013-02-19|Manufacturing process of derivatives of neuraminic acid
    KR101653064B1|2016-09-09|A Method for Gadobutrol
    JP6851149B2|2021-03-31|Method for producing piperidine compound
    US6388091B1|2002-05-14|Process for the preparation of 1,2,3,9-tetrahydro-9-methyl-3-{|methyl}-4H-carbazol-4-one
    JP2017521416A|2017-08-03|Method for producing 3-hydroxypicolinic acid
    US9359333B2|2016-06-07|Efficient process for the preparation of Lapatinib and salts thereof by means of new intermediates
    ES2528646T3|2015-02-11|Process for the manufacture of 1-alkyl-3-difluoromethyl-5-hydroxypyrazoles
    JP2020518573A|2020-06-25|Preparation of 2-|-benzoic acid derivative
    KR101842425B1|2018-05-14|New process for preparing Citalopram and Escitalopram
    EP2754662A1|2014-07-16|Efficient process for the preparation of Lapatinib and salts thereof by means of new intermediates
    EP2141151B1|2013-03-20|Method for producing 2-haloimidazole compound
    BR102018015115A2|2019-09-17|INTERMEDIATE PREPARATION PROCESS
    US20190010141A1|2019-01-10|Process for the synthesis of efinaconazol
    US20110071302A1|2011-03-24|Process for preparing intermediate compound for synthesizing an antiulcerant
    JP2010116370A|2010-05-27|Method for producing 2-aminotropones
    JP2015071572A|2015-04-16|Chromene triflones, coumarin triflones and their production method
    JP2010070535A|2010-04-02|2-benzyl-4,5-diphenylimidazole compound
    同族专利:
    公开号 | 公开日
    ES2556782T3|2016-01-20|
    EP2966071A1|2016-01-13|
    TW201215601A|2012-04-16|
    EP2612859A4|2014-01-08|
    US20130150586A1|2013-06-13|
    EP2966071B1|2017-01-25|
    EP2612859B1|2015-09-30|
    CN106045970B|2019-11-08|
    CN106045970A|2016-10-26|
    TWI518081B|2016-01-21|
    EP2612859A1|2013-07-10|
    WO2012029836A1|2012-03-08|
    BR112013004827A2|2016-05-31|
    CA2808230A1|2012-03-08|
    CN103080100A|2013-05-01|
    US8871942B2|2014-10-28|
    JPWO2012029836A1|2013-10-31|
    CA2808230C|2017-02-28|
    CN103080100B|2016-04-27|
    HUE026357T2|2016-06-28|
    PT2612859E|2015-11-30|
    RS54330B1|2016-02-29|
    PL2612859T3|2016-01-29|
    JP5852573B2|2016-02-03|
    DK2612859T3|2015-10-19|
    CY1116997T1|2017-04-05|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    JPH02191262A|1988-03-04|1990-07-27|Sankyo Co Ltd|Triazole derivative|
    CN1046278C|1993-05-10|1999-11-10|科研制药株式会社|Azolylamine derivative|
    KR100403246B1|1995-09-28|2004-02-11|가켄 세이야쿠 가부시키가이샤|Preparation of 4-methylenepiperidine|US20090175810A1|2008-01-03|2009-07-09|Gareth Winckle|Compositions and methods for treating diseases of the nail|
    US8039494B1|2010-07-08|2011-10-18|Dow Pharmaceutical Sciences, Inc.|Compositions and methods for treating diseases of the nail|
    CA2924748C|2013-10-03|2019-09-03|Dow Pharmaceutical Sciences, Inc.|Stabilized efinaconazole formulations|
    CN105848719A|2013-11-22|2016-08-10|道尔医药科学公司|Anti-infective methods, compositions, and devices|
    CN104292214B|2014-09-24|2017-04-05|南京华威医药科技开发有限公司|The synthetic method of Chinese mugwort Fluconazole and its intermediate|
    CN104327047B|2014-10-17|2016-04-06|苏州明锐医药科技有限公司|The preparation method of Ai Feikang azoles|
    WO2016079728A1|2014-11-23|2016-05-26|Mapi Pharma Ltd.|Intermediate compounds and process for the preparation of efinaconazole|
    EP3247399A4|2015-01-20|2018-09-05|Wavelength Enterprises Ltd|Crystalline forms of efinaconazole|
    ITUB20150417A1|2015-05-08|2016-11-08|Dipharma Francis Srl|PROCEDURE FOR THE PREPARATION OF PIPERIDINE COMPOUNDS|
    WO2016181306A1|2015-05-12|2016-11-17|Lupin Limited|Process for the preparation of efinaconazole|
    WO2016193917A1|2015-06-04|2016-12-08|Glenmark Pharmaceuticals Limited|Process for the preparation of efinaconazole|
    EP3112360A1|2015-06-29|2017-01-04|Dipharma Francis S.r.l.|Process for the preparation of efinaconazole|
    CN106565672A|2015-10-08|2017-04-19|中美华世通生物医药科技（武汉）有限公司|Method for preparation of Efinaconazole|
    US20170129874A1|2015-11-10|2017-05-11|Virupaksha Organics Limited|Novelimproved process for preparing a triazole antifungal agent|
    CN106810534A|2015-11-30|2017-06-09|中美华世通生物医药科技（武汉）有限公司|Chinese mugwort Fluconazole crystal formation and preparation method thereof|
    CN106918672B|2015-12-28|2021-02-09|中美华世通生物医药科技（武汉）有限公司|Method for measuring related substances in efinaconazole raw material medicine and preparation thereof by using HPLC|
    CN106928186A|2015-12-29|2017-07-07|中美华世通生物医药科技（武汉）有限公司|Compound and its production and use|
    ITUB20159795A1|2015-12-30|2017-06-30|Procos Spa|PROCESS FOR THE SYNTHESIS OF EFINACONAZOLE|
    CN106995434A|2016-01-25|2017-08-01|广东东阳光药业有限公司|A kind of crystal formation of triazole antifungal agent and preparation method thereof|
    ITUA20162545A1|2016-04-13|2017-10-13|Laboratorio Chimico Int S P A|Procedure for the preparation of intermediates useful in the synthesis of drugs|
    CN107759565B|2016-08-15|2020-10-23|苏州旺山旺水生物医药有限公司|Preparation method of 1-triazole-2-butanol derivative|
    CN107778283A|2016-08-26|2018-03-09|山东特珐曼药业有限公司|A kind of preparation method and its crystal formation M of the Fluconazole that ends|
    WO2018036416A1|2016-08-26|2018-03-01|山东特珐曼药业有限公司|Efinaconazole preparation method and crystal form m of efinaconazole|
    CN108276381A|2017-01-06|2018-07-13|上海和博药物研究有限公司|A kind of synthetic method of Chinese mugwort Fluconazole|
    IT201700048270A1|2017-05-04|2018-11-04|Seegpharm Sa|Process for the preparation of an azole derivative.|
    TW201906831A|2017-05-19|2019-02-16|日商科研製藥股份有限公司|Method for producing and purifying efinaconazole|
    CN108440390A|2018-03-13|2018-08-24|上药康丽（常州）药业有限公司|A kind of preparation method of 4- methylenepiperidines salt|
    CA3115742A1|2018-12-29|2020-07-02|Viwit Pharmaceutical Co., Ltd.|Preparation method for efinaconazole|
    法律状态:
    2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law|
    2018-04-03| B06F| Objections, documents and/or translations needed after an examination request according art. 34 industrial property law|
    2019-03-26| B07E| Notice of approval relating to section 229 industrial property law|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
    2019-05-28| B06T| Formal requirements before examination|
    2020-02-11| B09A| Decision: intention to grant|
    2020-03-31| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/08/2011, OBSERVADAS AS CONDICOES LEGAIS. |
    优先权:
    申请号 | 申请日 | 专利标题
    JP2010194068|2010-08-31|
    JP2010-194068|2010-08-31|
    PCT/JP2011/069733|WO2012029836A1|2010-08-31|2011-08-31|Method for producing 1-triazole-2-butanol derivative|
    [返回顶部]